All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2007-004023-38 | Prospective, multicentric, double-masked clinical study to compare the efficacy and safety of Ganfort and Duotrav in primary open angle and pseudoexfoliative glaucoma patients previously treated with ... | 2009-04-16 | due-trials |
Completed, but no date, and reported results | 2007-006235-31 | 12 MONTHS CASE SERIES OPEN STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTION OF LUCENTIS (RANIBIZUMAB 0.5 MG) USED IN COMBINATION WITH VISUDYNE (VERTEPORFIN PDT) IN NAIVE SIBJECTS WITH... | bad-data | |
Completed, but no date, and reported results Terminated | 2009-014444-11 | Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib | bad-data | |
Ongoing | 2010-020213-82 | Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients | not-yet-due | |
Ongoing | 2010-024272-26 | Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure Confronto tra gli effetti del Bimatoprost 0.01% e Timololo 0.5% sulla pressione intraoculare circa... | not-yet-due | |
Ongoing | 2011-000425-72 | Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection | not-yet-due | |
Completed, report not yet due | 2019-003426-24 | 24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK.... | 2024-02-27 | not-yet-due |